Dementia supplement comparison favored choline alphoscerate on a broad assessment
The review favored choline alphoscerate on an overall clinical scale, but found no clear differences in separate cognitive tests or dropouts.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
In people with dementia, the broad clinical assessment favored choline alphoscerate over citicoline at treatment's end. The review did not detect statistically significant differences on memory or word-fluency tests, or in dropout rates. The broader score advantage does not establish benefit across every cognitive outcome or applicability to people without dementia.
This summary relies on the abstract, which omits treatment lengths, doses and certainty ratings. Dropout rates cannot establish comprehensive safety; nonsignificant results do not prove equivalence.
What researchers found
Weighted mean difference in SCAG score units
Choline alphoscerate versus citicoline at treatment's end. Negative values favor choline alphoscerate; the abstract does not establish the clinical importance of this difference.
What the scale covered
The Sandoz Clinical Assessment for Geriatric Patients (SCAG) covered cognition, relationships, emotional symptoms, apathy and physical functioning. Results favored choline alphoscerate across these areas; separate memory and word-fluency tests showed no significant differences.
Limits of a direct comparison
The review compared supplements in people with dementia. It does not establish how either compares with no supplement, or whether either prevents dementia in people who do not have it.
The original publication
Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis.
Sagaro GG, Amenta F
Front Neurol · 2025
- PubMed ID
- 41426989
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.